RESUMO
Ischemic heart disease is the leading cause of death in the United States, Canada, and worldwide. Severe disease is characterized by coronary artery occlusion, loss of blood flow to the myocardium, and necrosis of tissue, with subsequent remodeling of the heart wall, including fibrotic scarring. The current study aims to demonstrate the efficacy of quantitating infarct size via two-dimensional (2-D) echocardiographic akinetic length and four-dimensional (4-D) echocardiographic infarct volume and surface area as in vivo analysis techniques. We further describe and evaluate a new surface area strain analysis technique for estimating myocardial infarction (MI) size after ischemic injury. Experimental MI was induced in mice via left coronary artery ligation. Ejection fraction and infarct size were measured through 2-D and 4-D echocardiography. Infarct size established via histology was compared with ultrasound-based metrics via linear regression analysis. Two-dimensional echocardiographic akinetic length (r = 0.76, P = 0.03), 4-D echocardiographic infarct volume (r = 0.85, P = 0.008), and surface area (r = 0.90, P = 0.002) correlate well with histology. Although both 2-D and 4-D echocardiography were reliable measurement techniques to assess infarct, 4-D analysis is superior in assessing asymmetry of the left ventricle and the infarct. Strain analysis performed on 4-D data also provides additional infarct sizing techniques, which correlate with histology (surface strain: r = 0.94, P < 0.001, transmural thickness: r = 0.76, P = 0.001). Two-dimensional echocardiographic akinetic length, 4-D echocardiography ultrasound, and strain provide effective in vivo methods for measuring fibrotic scarring after MI.NEW & NOTEWORTHY Our study supports that both 2-D and 4-D echocardiographic analysis techniques are reliable in quantifying infarct size though 4-D ultrasound provides a more holistic image of LV function and structure, especially after myocardial infarction. Furthermore, 4-D strain analysis correctly identifies infarct size and regional LV dysfunction after MI. Therefore, these techniques can improve functional insight into the impact of pharmacological interventions on the pathophysiology of cardiac disease.
Assuntos
Infarto do Miocárdio/diagnóstico por imagem , Ultrassonografia/métodos , Algoritmos , Animais , Débito Cardíaco , Feminino , Ventrículos do Coração/diagnóstico por imagem , Ventrículos do Coração/patologia , Ventrículos do Coração/fisiopatologia , Imageamento Tridimensional/métodos , Imageamento Tridimensional/normas , Masculino , Camundongos , Infarto do Miocárdio/patologia , Infarto do Miocárdio/fisiopatologia , Sensibilidade e Especificidade , Ultrassonografia/normasRESUMO
In an effort to develop a novel therapeutic agent aimed at addressing the unmet need of patients with osteoarthritis pain, we set out to develop an inhibitor for autotaxin with excellent potency and physical properties to allow for the clinical investigation of autotaxin-induced nociceptive and neuropathic pain. An initial hit identification campaign led to an aminopyrimidine series with an autotaxin IC50 of 500 nM. X-ray crystallography enabled the optimization to a lead compound that demonstrated favorable potency (IC50 = 2 nM), PK properties, and a robust PK/PD relationship.
RESUMO
While pharmacists have long been delivering personalized clinical patient services, recognition of pharmacists as health care providers, realization of the value of pharmacist cognitive services, and fair payment for pharmacists have been slow to evolve. This article tracks the evolution of medication therapy management (MTM) services provided by pharmacists, using the Medicare Modernization Act of 2003 as a springboard. The core elements of MTM services are discussed and reviewed, and MTM programs and services as outlined in the Medicare Part D outpatient prescription drug benefit are thoroughly examined. Pharmacist and patient perceptions of the value of MTM are outlined, and barriers to MTM implementation at the pharmacy/pharmacist level are evaluated. Key studies showing the economic and clinical benefits of MTM services are discussed, as well as important drivers that may propel MTM beyond the Medicare Part D threshold.
Assuntos
Assistência Ambulatorial , Atenção à Saúde , Conduta do Tratamento Medicamentoso , Assistência Farmacêutica , Farmacêuticos , Medicamentos sob Prescrição , Pessoal de Saúde , Humanos , Medicare Part D , Papel Profissional , Estados UnidosRESUMO
The disclosed 3-phenyl-5-isothiazole carboxamides are potent allosteric antagonists of mGluR1 with generally good selectivity relative to the related group 1 receptor mGluR5. Pharmacokinetic properties of a member of this series (1R,2R)-N-(3-(4-methoxyphenyl)-4-methylisothiazol-5-yl)-2-methylcyclopropanecarboxamide (14) are good, showing acceptable plasma and brain exposure after oral dosing. Oral administration of isothiazole 14 gave robust activity in the formalin model of persistent pain which correlated with CNS receptor occupancy.
Assuntos
Amidas/síntese química , Analgésicos/síntese química , Antagonistas de Aminoácidos Excitatórios/síntese química , Dor/tratamento farmacológico , Receptores de Glutamato Metabotrópico/antagonistas & inibidores , Tiazóis/síntese química , Administração Oral , Amidas/administração & dosagem , Amidas/farmacocinética , Analgésicos/administração & dosagem , Analgésicos/farmacocinética , Animais , Disponibilidade Biológica , Encéfalo/metabolismo , Antagonistas de Aminoácidos Excitatórios/administração & dosagem , Antagonistas de Aminoácidos Excitatórios/farmacocinética , Humanos , Dor/metabolismo , Medição da Dor , Ratos , Ratos Sprague-Dawley , Receptores de Glutamato Metabotrópico/metabolismo , Estereoisomerismo , Relação Estrutura-Atividade , Tiazóis/administração & dosagem , Tiazóis/farmacocinéticaRESUMO
Part 1 of this series provided an introduction and overview of the medication regimen review (MRR) process (Consult Pharm 2010;25:710-20). In Part 2, a framework for MRR was presented (Consult Pharm 2010;25:778-802). This article reviews and expands on the elements of the MRR framework and provides examples of implementation.
Assuntos
Revisão de Uso de Medicamentos , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Farmacêuticos , Consultores , HumanosRESUMO
The medication regimen review is considered the core activity of the consultant pharmacist. This article, the first in a series of three, will provide an introduction and overview of the medication regimen review. Goals of the MRR will be presented, along with a discussion of the different types of MRR. The importance of focusing on the values, priorities, and goals of each individual patient is emphasized. Other articles in this series will provide more specifics about the medication regimen review process.
Assuntos
Revisão de Uso de Medicamentos/métodos , Preparações Farmacêuticas/administração & dosagem , Farmacêuticos/organização & administração , Consultores , Humanos , Assistência Farmacêutica/organização & administração , Papel ProfissionalRESUMO
Drug therapy is one of a variety of tools used by clinicians to manage symptoms and diseases in patients. To understand the medication regimen review process, it is important to understand the big picture of patient care and how medications fit into this overall scheme. The framework for patient management is known as "the care process."
Assuntos
Tratamento Farmacológico , Revisão de Uso de Medicamentos/métodos , Monitoramento de Medicamentos/métodos , Humanos , Assistência ao Paciente/métodos , Preparações Farmacêuticas/administração & dosagemAssuntos
Doença de Alzheimer , Inibidores da Colinesterase/uso terapêutico , Medicina Baseada em Evidências , Avaliação Geriátrica/métodos , Idoso , Idoso de 80 Anos ou mais , Doença de Alzheimer/diagnóstico , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/economia , Inibidores da Colinesterase/efeitos adversos , Donepezila , Humanos , Indanos/uso terapêutico , Transtornos Mentais/tratamento farmacológico , Transtornos Mentais/etiologia , Transtornos Mentais/terapia , Nootrópicos/efeitos adversos , Nootrópicos/uso terapêutico , Fenilcarbamatos/uso terapêutico , Piperidinas/uso terapêutico , Tomografia por Emissão de Pósitrons , Rivastigmina , Tacrina/uso terapêuticoRESUMO
Structure-activity relationship (SAR) studies on the tricyclic isoxazole series of MRP1 modulators have resulted in the identification of potent and selective inhibitors containing cyclohexyl-based linkers. These studies ultimately identified compound 21b, which reverses drug resistance to MRP1 substrates, such as doxorubicin, in HeLa-T5 cells (EC(50)=0.093microM), while showing no inherent cytotoxicity. Additionally, 21b inhibits ATP-dependent, MRP1-mediated LTC(4) uptake into membrane vesicles prepared from the MRP1-overexpressing HeLa-T5 cells (EC(50)=0.064microM) and shows selectivity (1115-fold) against the related transporter, P-glycoprotein, in HL60/Adr and HL60/Vinc cells. Finally, when dosed in combination with the oncolytic MRP1 substrate vincristine, 21b showed tumor regression and growth delay in MRP1-overexpressing tumors in vivo.
Assuntos
Isoxazóis/farmacologia , Proteínas Associadas à Resistência a Múltiplos Medicamentos/antagonistas & inibidores , Antineoplásicos/síntese química , Antineoplásicos/farmacologia , Células HeLa , Humanos , Isoxazóis/síntese química , Cinética , Conformação Molecular , Relação Estrutura-AtividadeRESUMO
A novel structural class of picornavirus inhibitors comprising an imidazo[1,2-b]pyridazine nucleus was discovered. 2-Aminoimidazo[1,2-b]pyridazines (6d, (E/Z)-7b, (E)-7d, (Z)-7d, (E/Z)-8b, (E)-10b, (E)-13a, (Z)-13a, (E)-13b, (Z)-13b, (E)-13c, and (Z)-13c) were designed and synthesized in an effort to identify potent broad spectrum antirhinoviral agents. A practical synthetic route to this chemical scaffold has been developed. The target compounds were evaluated in a plaque reduction assay and in a cytopathic effect assay. Our preliminary SAR studies highlight the minimum structural features required for antirhinovirus activity. Our data suggest that the nature of the linker between the phenyl and the imidazopyridazine moieties has a significant influence on the activity of these compounds. Oximes are slightly better than vinyl carboxamides at this position. The oximes are the most potent analogues against human rhinovirus 14 (HRV-14), and at the concentrations evaluated, no apparent cellular toxicity is noted. Furthermore, the E geometry appears to be a key element for activity; the Z isomer leads to a considerable loss in potency. Of particular interest, analogue 7b exhibits potent broad-spectrum antirhinoviral and antienteroviral activity when evaluated against a panel of seven additional rhino- and enteroviruses. The chemistry and the biological evaluations are discussed.
Assuntos
Antivirais/química , Antivirais/farmacologia , Imidazóis/química , Imidazóis/farmacologia , Picornaviridae/efeitos dos fármacos , Piridazinas/química , Piridazinas/farmacologia , Antivirais/síntese química , Desenho de Fármacos , Humanos , Imidazóis/síntese química , Isomerismo , Piridazinas/síntese química , Relação Estrutura-AtividadeRESUMO
Tricyclic isoxazoles were identified from a screen as a novel class of selective multidrug resistance protein (MRP1) inhibitors. From a screen lead, SAR efforts resulted in the preparation of LY 402913 (9h), which inhibits MRP1 and reverses drug resistance to MRP1 substrates, such as doxorubicin, in HeLa-T5 cells (EC(50)=0.90 microM), while showing no inherent cytotoxicity. Additionally, LY 402913 inhibits ATP-dependent, MRP1-mediated LTC(4) uptake into membrane vesicles prepared from the MRP1-overexpressing HeLa-T5 cells (EC(50)=1.8 microM). LY 402913 also shows selectivity ( approximately 22-fold) against the related transporter, P-glycoprotein, in HL60/Adr and HL60/Vinc cells. Finally, when dosed in combination with the oncolytic MRP1 substrate vincristine, LY 402913 delays the growth of MRP1-overexpressing tumors in vivo.